The use of HDAC inhibitors, which are most commonly utilized as broad-spectrum agents inhibiting the activity of multiple HDAC isotypes, is emerging as an effective cancer treatment strategy [41, 42], and several inhibitors are in phase I-III clinical trials. Here, HDAC9 is linked to cancer.